Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
News|Articles|May 13, 2014
Eurofins to Acquire ViraCor-IBT Laboratories
Author(s)Pharmaceutical Technology Editors
Eurofins Scientific will acquire ViraCor-IBT Laboratories for $255 million.
Advertisement
Eurofins reports that the acquisition will strengthen both its pharmaceutical and genomic service offerings and establish a presence in the specialty clinical testing services for infectious disease, immunology, allergy, HLA, and serology. The transaction also includes retaining VIBT’s 270 employees.
Upon closing of the transaction the company will continue to be known as ViraCor-IBT Laboratories. Completion of the transaction is expected in the next 60 days.
Source:
Advertisement
Related to this article
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
Vibha Jawa, PhD, chief scientific officer at EpiVax, discusses the limitations of current preclinical testing approaches and how new approach methodologies can strengthen drug development.
Pauric Bannigan, Intrepid Labs, explains how physics-informed machine learning aids formulation and why regulators still want experimental data.
Vibha Jawa, PhD, chief scientific officer at EpiVax, explains why the need for animal studies varies by modality and what it takes for organ-on-chip and other human-relevant models to replace these studies in IND-enabling toxicology work.
Sanjay Konagurthu, PhD, senior director of Science and Innovation at Thermo Fisher Scientific, explains what teams need to do to ensure the usefulness of AI and what strides have been made with AI in regulatory submissions.
Pauric Bannigan, Intrepid Labs, explains where AI speeds formulation decisions, why data is the bottleneck, and how active learning trains models with far less data.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: Roller-Compacted Formulations
2
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
AAPS PharmSci 360 2026: AI in Drug Delivery
5